1. ALLA AKTIER
  2. NYHETER
  3. ACTIVE BIOTECH

Active Biotech

Nyheter Active Biotech Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Annual Report 2025 Active Biotech AB (publ)

REG

Active Biotech (NASDAQ Stockholm:ACTI) announces today that the Annual Report 2025 now is available for download at www.activebiotech.com.

The Annual Report will only be digitally distributed.

“Building on progress in 2025, the coming year will focus on the tasquinimod clinical studies in myelofibrosis and intensified business development for laquinimod,” says Active Biotech CEO Helén Tuvesson.

For further information, please contact:

Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies have been initiated. Laquinimod is in development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation has been performed to support phase II development together with a partner. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

This information is information that Active Biotech is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-04-01 09:30 CEST.

Attachments

Active Biotech 2025 Eng

Datum 2026-04-01, kl 09:30
Källa MFN
Bifogade filer
Active Biotech 2025 Eng